Patients'characteristic survey concomitantly to the Post Marketing Surveillance(PMS) of Spiriva Respimat

Patients'characteristic survey concomitantly to the Post Marketing Surveillance(PMS) of Spiriva Respimat - Patients'characteristic survey

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000017640

Enrollment

300

Registered

2015-05-22

Start date

2015-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial asthma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients diagnosed with severe persistent bronchial asthma 2)Patients aged >= 15 years 3)Patients who receive ICS maintenance therapy and at least one anti-asthmatic drug (LABA, leukotriene modifier, xanthines, anti-IgE antibody and oral corticosteroid) except for Spiriva Respimat. 4)Patients with informed consent sequentially enrolled in the same hospitals, the same clinics and by the same physicians as the PMS study during the same period

Exclusion criteria

Exclusion criteria: 1)Patients who have a contraindication to Spiriva Respimat defined in the package insert for Spiriva Respimat 2)Patients who have been enrolled this study before

Design outcomes

Primary

Measure	Time frame
Patients characteristics (sex, birth day, height, weight, smoking status/pack-year, asthma severity, date of onset,the number of hospitalizations and emergency visits), condition of new prescription of anti-asthma drugs, medical history/concomitant disease, concomitant medication, concomitant therapy, pulmonary function test, level of asthma control, QOL	—

Countries

Japan

Contacts

Public ContactYasunori Suga

Nippon Boehringer Ingelheim Co.,LTD Clinical Development & Medical Affairs,Medical Development, Medicine & QRPE

yasunori.suga@boehringer-ingelheim.com03-6417-2228

Outcome results